146 related articles for article (PubMed ID: 35102712)
1. A modeling-based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics study.
Keutzer L; Akhondipour Salehabad Y; Davies Forsman L; Simonsson USH
CPT Pharmacometrics Syst Pharmacol; 2022 May; 11(5):628-639. PubMed ID: 35102712
[TBL] [Abstract][Full Text] [Related]
2. Optimized Loading Dose Strategies for Bedaquiline When Restarting Interrupted Drug-Resistant Tuberculosis Treatment.
Koele SE; van Beek SW; Maartens G; Brust JCM; Svensson EM
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0174921. PubMed ID: 35007141
[TBL] [Abstract][Full Text] [Related]
3. Addressing bedaquiline treatment interruptions in the treatment of drug-resistant TB.
Kambili C; Rossenu S; Hoetelmans RMW; Birmingham E; Bakare N
Int J Tuberc Lung Dis; 2022 Jul; 26(7):671-677. PubMed ID: 35768912
[TBL] [Abstract][Full Text] [Related]
4. Exposure-safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug-resistant tuberculosis.
Tanneau L; Svensson EM; Rossenu S; Karlsson MO
CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1538-1549. PubMed ID: 34626526
[TBL] [Abstract][Full Text] [Related]
5. Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis.
Perrineau S; Lachâtre M; Lê MP; Rioux C; Loubet P; Fréchet-Jachym M; Gonzales MC; Grall N; Bouvet E; Veziris N; Yazdanpanah Y; Peytavin G
Int J Tuberc Lung Dis; 2019 Jan; 23(1):99-104. PubMed ID: 30674381
[TBL] [Abstract][Full Text] [Related]
6. Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
Doan TN; Cao P; Emeto TI; McCaw JM; McBryde ES
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249697
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients.
Ardhianto D; Suharjono ; Soedarsono ; Fatmawati U
J Basic Clin Physiol Pharmacol; 2021 Jun; 32(4):421-427. PubMed ID: 34214323
[TBL] [Abstract][Full Text] [Related]
8. Development and Validation of a Nomogram for Prediction of QT Interval Prolongation in Patients Administered Bedaquiline-Containing Regimens in China: a Modeling Study.
Liu F; Gao J; Gao M; Liu Y; Shu W; Xie L; Sun Y; Zhang L; Li L; Pang Y
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0203321. PubMed ID: 36047781
[TBL] [Abstract][Full Text] [Related]
9. Bedaquiline Effect on QT Interval of Drugs-Resistant Tuberculosis Patients: Real World Data.
Darmayani IGAAPS; Ascobat P; Instiaty I; Sugiri YJR; Sawitri N
Acta Med Indones; 2022 Jul; 54(3):389-396. PubMed ID: 36156479
[TBL] [Abstract][Full Text] [Related]
10. Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients.
Barvaliya SV; Desai MK; Panchal JR; Solanki RN
Indian J Tuberc; 2020 Apr; 67(2):222-230. PubMed ID: 32553316
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis.
Maartens G; Brill MJE; Pandie M; Svensson EM
Int J Tuberc Lung Dis; 2018 Jan; 22(1):26-29. PubMed ID: 29145924
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis.
Salhotra VS; Sachdeva KS; Kshirsagar N; Parmar M; Ramachandran R; Padmapriyadarsini C; Patel Y; Mehandru L; Jaju J; Ponnuraja C; Gupta M; Kalaiselvan V; Shamim A; Khaparde S; Swaminathan S;
Indian J Tuberc; 2020 Jan; 67(1):29-37. PubMed ID: 32192613
[TBL] [Abstract][Full Text] [Related]
13. Dose- and Time-dependency of the Toxicity and Pharmacokinetic Profiles of Bedaquiline and Its N-desmethyl Metabolite in Dogs.
Smyej I; De Jonghe S; Looszova A; Mannens G; Verhaeghe T; Thijssen S; Starckx S; Lampo A; Rouan MC
Toxicol Pathol; 2017 Jul; 45(5):663-675. PubMed ID: 28789609
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
[TBL] [Abstract][Full Text] [Related]
15. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis in China.
Han X; Chen X; Sha W; Zhang X; Qiu L; Wang J; Wu G; Yao L; Lv Y; Zhang X; Zhou J; Tang S; Chu N
Int J Tuberc Lung Dis; 2020 Aug; 24(8):789-794. PubMed ID: 32912383
[No Abstract] [Full Text] [Related]
16. Modeling the impact of bedaquiline treatment strategies on the multidrug-resistant tuberculosis burden in India.
Mehra M; Kambili C; Potluri R; Rhines A; Singh V; Thomas A
Int J Tuberc Lung Dis; 2017 Aug; 21(8):902-909. PubMed ID: 28786799
[TBL] [Abstract][Full Text] [Related]
17. Bedaquiline for multidrug-resistant TB in paediatric patients.
Moodliar R; Aksenova V; Frias MVG; van de Logt J; Rossenu S; Birmingham E; Zhuo S; Mao G; Lounis N; Kambili C; Bakare N
Int J Tuberc Lung Dis; 2021 Sep; 25(9):716-724. PubMed ID: 34802493
[TBL] [Abstract][Full Text] [Related]
18. Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant
Almeida D; Converse PJ; Li SY; Upton AM; Fotouhi N; Nuermberger EL
Antimicrob Agents Chemother; 2021 Nov; 65(12):e0141221. PubMed ID: 34570644
[TBL] [Abstract][Full Text] [Related]
19. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis.
Liu Y; Gao J; Du J; Shu W; Wang L; Wang Y; Xue Z; Li L; Xu S; Pang Y
Int J Infect Dis; 2021 Jan; 102():392-396. PubMed ID: 33130209
[TBL] [Abstract][Full Text] [Related]
20. Emergence of nontuberculous mycobacteria infections during bedaquiline-containing regimens in multidrug-resistant tuberculosis patients.
Gao J; Pei Y; Yan X; Shi G; Li T; Gao M; Liu Y; Wang Y; Shu W; Li L; Pang Y
Int J Infect Dis; 2020 Nov; 100():196-198. PubMed ID: 32890726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
